SPY295.44+0.56 0.19%
DIA244.88-0.14 -0.06%
IXIC9,324.59+39.71 0.43%

Unum Therapeutics Says Was Notified By FDA That Partial Clinical Hold On Phase 1 Trial Of ACTR707 In Combination With Rituximab Has Been Lifted

On March13, 2020, Unum Therapeutics Inc. (“Unum”) was notified by the U.S. Food& Drug Administration (FDA) that the partial clinical hold placed on its Phase 1 trial (ATTCK-20-03) of ACTR707 in

Benzinga · 03/16/2020 11:37

On March13, 2020, Unum Therapeutics Inc. (“Unum”) was notified by the U.S. Food& Drug Administration (FDA) that the partial clinical hold placed on its Phase 1 trial (ATTCK-20-03) of ACTR707 in combination with rituximab in patients with CD20+ B cell non-Hodgkin lymphoma (r/r NHL) has been lifted.

The partial clinical hold was initiated on March4, 2020 following the submission of a safety report by Unum to the FDA regarding one patient in the trial who experienced a Grade 3 serious adverse event that was being evaluated as a possible new malignancy and was considered to be possibly related to ACTR707. Following the submission of a response to a request for information from the FDA, Unum has been notified by the FDA that the partial clinical hold was lifted.